Genome-wide analysis of Ollier disease: Is it all in the genes?

Table 1 Clinicopathological data of the Ollier patients

Patient ID	Sample	Tumor Grade	Tumor location	Gender	Age	Application
17	L1083	CS I	metacarpal	M	48	1,3
17	L2218	CS I	phalanx	M	49	1,3
20	L286*	CS II	femur	F	23	1,3
21	L204*	CS I	femur	M	26	1,3
21	L253*	CS I	tibia	M	26	1,3
22	L206	EC	phalanx	F	26	1,2,3,4
22	L910	EC	phalanx	F	16	1,2,3,4
23	L813	CS II	humerus	M	68	1,3
25	L1251*	EC	phalanx	M	15	1,2,3,4
25	L2220*	EC	metacarpal	M	14	1,3,4
26	L1974	CS II	scapula	M	48	1,3
27	L1975*	CS II	femur	M	31	1,3
28	L1976*	CS II	tibia	M	41	1,3
29	L1977*	CS I	tibia	M	41	1,3
29	L1978*	EC	foot	M	38	1,3
30	L1980	CS II	knee	F	63	1,3
31	L810	CS III	unknown	M	-	1,3
33	L1685	CS I	pubic bone	F	23	1,3
34	L1687	CS I	phalanx	M	18	1,3
34	L1686	EC	phalanx	M	18	1,2,3,4
35	L2386	CS I	phalanx	F	13	1,3
36	L2463*	EC	tibia	F	12	1,3
38	L1629	EC	unknown	M	36	1,3
38	L1630	EC	Iliac bone	M	36	1,2,3,4
42	L2098	CS II	humerus	F	15	1,3
43	L2099	CS II	humerus	F	49	1,3
47	L2103a	EC	phalanx	M	39	1,2,3,4
47	L2103b	CS I	phalanx	M	39	1,3
48	L2104a	CS III	tibia	M	35	1,3
48	L2104b	EC	femur	M	35	1,3
50	L2221*	CS I	femur	F	42	1,3
52	L1513*	CS I	femur	F	23	1,3
54	L1490*	EC	phalanx	F	12	1,3
61	L2205	EC	ilium	M	6	1,3
64	L1683	EC	metacarpal	F	29	1,2,3,4
68	L2280*	CS I	acromion	F	24	1,3
69	L2513	CS I	pelvis	M	33	1,3

* Normal DNA available enabling paired analysis. Application - 1: sample used for SNP array, 2: expression array, 3: MLPA and 4: qRT-PCR.

ISSN: 1750-1172